Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Vascular pharmacology

• Publication date

  2015-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.vph.2015.06.001PMID 26071862
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early stent thrombosis with bivalirudin in patients undergoing percutaneous coronary intervention

  2015cited by this paper
• Relationship between changes in platelet reactivity and ischemic events following percutaneous coronary intervention: a meta-regression analysis of 30 randomized trials.

  2014cited by this paper
• Intracoronary versus intravenous bolus abciximab administration in patients undergoing primary percutaneous coronary intervention with acute ST-elevation myocardial infarction: a pooled analysis of individual patient data from five randomised controlled trials.

  2014cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous

  2014cited by this paper
• Benefits From New ADP Antagonists as Compared With Clopidogrel in Patients With Stable Angina or Acute Coronary Syndrome Undergoing Invasive Management: A Meta-analysis of Randomized Trials

  2014cited by this paper
• 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Ca

  2014cited by this paper
• No-Reflow Phenomenon

  2014cited by this paper
• Randomized trial of standard versus ClearWay-infused abciximab and thrombectomy in myocardial infarction: rationale and design of the COCTAIL II study

  2013cited by this paper
• Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: cardiac magnetic resonance substudy of the AIDA STEMI trial.

  2013cited by this paper
• Impact of Diabetes on Long-Term Outcome After Primary Angioplasty

  2013cited by this paper
• Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial.

  2012cited by this paper
• Short- and Long-Term Mortality After Myocardial Infarction in Patients With and Without Diabetes

  2012cited by this paper
• Platelet inhibition and GP IIb/IIIa receptor occupancy by intracoronary versus intravenous bolus administration of abciximab in patients with ST-elevation myocardial infarction

  2012cited by this paper
• Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial.

  2012cited by this paper
• Intracoronary compared to intravenous bolus abciximab during primary percutaneous coronary intervention in ST-segment Elevation Myocardial Infarction (STEMI) patients reduces 30-day mortality and target vessel revascularization: a randomized trial.

  2011cited by this paper
• Prognostic significance and determinants of myocardial salvage assessed by cardiovascular magnetic resonance in acute reperfused myocardial infarction

  2010cited by this paper
• Local delivery versus intracoronary infusion of abciximab in patients with acute coronary syndromes.

  2010cited by this paper
• Intracoronary Versus Intravenous Administration of Abciximab in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention With Thrombus Aspiration: The Comparison of Intracoronary Versus Intravenous Abciximab Administration During Emergency Reperf

  2010cited by this paper
• Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention--effects on soluble CD40 ligand concentrations.

  2009cited by this paper
• Factors Contributing to Increased Platelet Reactivity in People With Diabetes

  2009cited by this paper
• Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.

  2009cited by this paper
• Intracoronary Compared With Intravenous Bolus Abciximab Application in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: The Randomized Leipzig Immediate Percutaneous Coronary Intervention Abciximab IV Versus IC in ST-Elevation Myocardial Infarct

  2008cited by this paper
• Hyperglycemia Is Associated With Enhanced Thrombin Formation, Platelet Activation, and Fibrin Clot Resistance to Lysis in Patients With Acute Coronary Syndrome

  2008cited by this paper
• Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions

  2007cited by this paper
• Rationale for intracoronary administration of abciximab

  2007cited by this paper
• Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

  2005cited by this paper
• Acute hyperglycaemia: a 'new' risk factor during myocardial infarction.

  2005cited by this paper
• Impact of diabetes mellitus on myocardial perfusion after primary angioplasty in patients with acute myocardial infarction.

  2005cited by this paper
• Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

  2003cited by this paper
• Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.

  2003cited by this paper
• An Additional Mechanism of Action of Abciximab: Dispersal of Newly Formed Platelet Aggregates

  2002cited by this paper
• Disaggregation of In Vitro Preformed Platelet-Rich Clots by Abciximab Increases Fibrin Exposure and Promotes Fibrinolysis

  2001cited by this paper
• Elevated ambient glucose induces acute inflammatory events in the microvasculature: effects of insulin.

  2001cited by this paper
• Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.

  2001cited by this paper
• Effects of Abciximab on the Architecture of Platelet-Rich Clots in Patients With Acute Myocardial Infarction Undergoing Primary Coronary Intervention

  2001cited by this paper
• Circulating adhesion molecules in humans: role of hyperglycemia and hyperinsulinemia.

  2000cited by this paper
• Diabetes enhances leukocyte accumulation in the coronary microcirculation early in reperfusion following ischemia.

  2000cited by this paper
• Abciximab reduces mortality in diabetics following percutaneous coronary intervention.

  2000cited by this paper
• Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction.

  1999cited by this paper
• Evidence for abnormal platelet glycoprotein expression in diabetes mellitus

  1990cited by this paper
• Guidelines on Myocardial Revascularization the Task Force on Myocardial Revascularization of the European Society of Cardiology (esc) and the European Association for Cardio-thoracic Surgery (eacts) Developed with the Special Contribution of the European Association for Percutaneous Cardiovascular I

  year unknowncited by this paper

• Therapeutic potential of integrins in diabetic retinopathy

  2025cites this paper
• Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention.

  2019cites this paper
• Effect of Diabetes Mellitus on Frequency of Adverse Events in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention.

  2016cites this paper
• Pooled Analysis Comparing the Efficacy of Intracoronary Versus Intravenous Abciximab in Smokers Versus Nonsmokers Undergoing Primary Percutaneous Coronary Revascularization for Acute ST-Elevation Myocardial Infarction.

  2016cites this paper
• Thrombus Aspirated from Patients with ST-Elevation Myocardial Infarction: Association between 3-Nitrotyrosine and Inflammatory Markers - Insights from ARTERIA Study

  2016cites this paper
• 1-Year Outcomes With Intracoronary Abciximab in Diabetic Patients Undergoing Primary Percutaneous Coronary Intervention.

  2016cites this paper
• Intracoronary vs intravenous abciximab in interventional cardiology: A reopened question?

  2015cites this paper
• World Journal of Diabetes

  year unknowncites this paper